NRX Pharmaceuticals, Inc. $NRXP

What the company doesAI summary of filing

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders including suicidal depression, chronic pain, PTSD, and schizophrenia. The company's three lead drug candidates are NRX-100 (a preservative-free ketamine formulation for intravenous infusion), KETAFREE (a generic preservative-free ketamine), and NRX-101 (an oral fixed-dose combination of D-cycloserine and lurasidone), all in FDA submission processes. NRx is also the founder and majority owner of HOPE Therapeutics, a medical services company that became revenue-generating in the fourth quarter of 2025 by acquiring and operating psychiatric clinics offering interventional psychiatry care including ketamine therapy, transcranial magnetic stimulation, and other neuroplastic treatments. The company currently makes money through HOPE's clinical operations and is pre-revenue from its pharmaceutical candidates, which target treatment-resistant and suicidal depression and related conditions through NMDA receptor modulation. [10-K 2026-03-23]

Segments: NRX-100 (preservative-free intravenous ketamine), KETAFREE (generic preservative-free ketamine), NRX-101 (D-cycloserine and lurasidone combination), HOPE Therapeutics (interventional psychiatry clinical services)